Orexo is a fully integrated specialty pharmaceutical company
Opioid addiction is a treatable chronic disease
Developed 4 products approved worldwide
Embracing all aspects of opioid addiction
We will be recognized for the added value our products bring to patients and societies
Orexo’s share is listed on Nasdaq Stockholm Mid Cap and available as American Depository Receipts (ADRs) on OTCQX in the US.
Follow Orexo in social media
From last week - another great article covering Orexo’s #vorvida deal with @GAIA_COM by @MedtechCate at… https://t.co/b0VQfDty8N
Save the Date -> #orexo invites investors, analysts and media to a Capital Markets Day on March 17, 2020.… https://t.co/SHuJgma6fR
#orexo strengthen its competencies and resources within digital health by appointing Dennis Urbaniak, one of the le… https://t.co/KzxddJevde
When you sign up to our newsletter or press releases, we use the data necessary for this purpose, or the data separately provided by you, to send you our email regularly. You can unsubscribe from our newsletter or press releases at any time via a link provided in the email.